2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib. (September 2015) - Banerjee, S.; Ledermann, J.; Matulonis, U.; Molife, L.R.; Friedlander, M.; Fielding, A.; Robertson, J.D.; Spencer, S.; McMurtry, E.; Kaye, S.